title: A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck.
abstract: Nab-paclitaxel might impact efficacy of radiation for head and neck (H&N) cancer. Nab-paclitaxel, cisplatin, cetuximab, and radiation were evaluated in patients with locally advanced head and neck cancer in this phase I/II trial. Median follow-up was 24 months for 34 patients. The maximum tolerated dose of nab-paclitaxel was 20 mg/m2with 20 mg/m2cisplatin and 250 mg/m2cetuximab. The 2-year progression-free survival (PFS) was 60% (95% confidence interval (CI) 0.42, 0.78), local control 71% (95% CI 0.55, 0.87), and overall survival 68% (95% CI 0.50, 0.86). This is the first study evaluating these agents with radiation in humans, with similar 2-year PFS as historic control.
authors.affiliation: a Division of Radiation Oncology, M.D. Anderson Comprehensive Cancer Center , Houston , TX , USA.
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Chun
authors.affiliation: b Division of Hematology and Oncology, Department of Internal Medicine, Harold C. Simmons Cancer Center, University of Texas at Southwestern Medical Center , Dallas , TX , USA.
authors.forename: Randall
authors.initials: R
authors.lastname: Hughes
authors.affiliation: c Department of Otolaryngology , University of Texas at Southwestern Medical Center , Dallas , TX , USA.
authors.forename: Baran D
authors.initials: BD
authors.lastname: Sumer
authors.affiliation: c Department of Otolaryngology , University of Texas at Southwestern Medical Center , Dallas , TX , USA.
authors.forename: Larry L
authors.initials: LL
authors.lastname: Myers
authors.affiliation: c Department of Otolaryngology , University of Texas at Southwestern Medical Center , Dallas , TX , USA.
authors.forename: John M
authors.initials: JM
authors.lastname: Truelson
authors.affiliation: b Division of Hematology and Oncology, Department of Internal Medicine, Harold C. Simmons Cancer Center, University of Texas at Southwestern Medical Center , Dallas , TX , USA.
authors.forename: Saad A
authors.initials: SA
authors.lastname: Khan
authors.affiliation: d Department of Clinical Sciences , University of Texas at Southwestern Medical Center , Dallas , TX , USA.
authors.forename: Tsung-Wei
authors.initials: TW
authors.lastname: Ma
authors.affiliation: d Department of Clinical Sciences , University of Texas at Southwestern Medical Center , Dallas , TX , USA.
authors.forename: Yang
authors.initials: Y
authors.lastname: Xie
authors.affiliation: e Valley Radiation Therapy Center , Anchorage , AK , USA.
authors.forename: John S
authors.initials: JS
authors.lastname: Yordy
authors.affiliation: f Department of Radiation Oncology , Harold C. Simmons Comprehensive Cancer Center, University of Texas at Southwestern Medical Center , Dallas , TX , USA.
authors.forename: Susan
authors.initials: S
authors.lastname: Cooley
authors.affiliation: f Department of Radiation Oncology , Harold C. Simmons Comprehensive Cancer Center, University of Texas at Southwestern Medical Center , Dallas , TX , USA.
authors.forename: Jean
authors.initials: J
authors.lastname: Wu
authors.affiliation: f Department of Radiation Oncology , Harold C. Simmons Comprehensive Cancer Center, University of Texas at Southwestern Medical Center , Dallas , TX , USA.
authors.forename: Hak
authors.initials: H
authors.lastname: Choy
authors.affiliation: f Department of Radiation Oncology , Harold C. Simmons Comprehensive Cancer Center, University of Texas at Southwestern Medical Center , Dallas , TX , USA.
authors.forename: Lucien A
authors.initials: LA
authors.lastname: Nedzi
mesh_terms: D000368:Aged; D000418:Albumins / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D000068818:Cetuximab / Q000008:administration & dosage / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D017239:Paclitaxel; D000068818:Cetuximab; D002945:Cisplatin
keywords: Abraxane; cisplatin; erbitux; head and neck cancer; radiation therapy